Novo Nordisk A/S (ADR) (NVO) was Initiated by Piper Jaffray to “Neutral”. Piper Jaffray advised their investors in a research report released on Sep 23, 2016.
Many Wall Street Analysts have commented on Novo Nordisk A/S (ADR). Novo Nordisk A/S (ADR) was Upgraded by Exane BNP Paribas to ” Outperform” on Sep 13, 2016. Novo Nordisk A/S (ADR) was Downgraded by JP Morgan to ” Neutral” on Sep 9, 2016. Novo Nordisk A/S (ADR) was Downgraded by Morgan Stanley to ” Equal-Weight” on Sep 1, 2016.
Novo Nordisk A/S (ADR) closed down -0.47 points or -1.02% at $45.57 with 23,46,457 shares getting traded on Thursday. Post opening the session at $45.81, the shares hit an intraday low of $45.41 and an intraday high of $45.92 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery development manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Company’s diabetes care segment covers insulins GLP-1 other protein-related products (such as glucagon protein-related delivery systems and needles) oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark and internationally in the United States France China and Brazil.